Argus has downgraded Silk Road Medical to hold after CMS covered a competing product. Read more here.
Oppenheimer has initiated coverage on Silk Road Medical Inc (NASDAQ: SILK ) with an Outperform rating and price target of $30 . Analysts Suraj Kalia and Shaymus Contorno note that Silk Road Medical has been at the forefront of introducing the Transcarotid Artery Revascularization (TCAR) method, an innovative procedure for stroke prevention in patients with carotid stenosis. Since its approval in 2015, SILK''s revenues have grown impressively, with a four-year CAGR of 42%, leading to yearly sales of around $182 … Full story available on Benzinga.com